3 results
Approved WMORecruiting
This study is being carried out to investigate the treatment with benralizumab in patients with active HES.The purpose of this study is to see if benralizumab, given as injections under the skin, can help control your HES better if it is added to…
Approved WMORecruiting
To prove that the RECAP test has the potential of selecting patients who are sensitive to treatment with the PARP inhibitor talazoparib as measured by the PFS rate at 4 months.
Approved WMORecruiting
Primary objectiveTo demonstrate that talazoparib in combination with enzalutamide is superior to placebo in combination with enzalutamide in prolonging investigator--assessed Radiographic Progression-free Survival (rPFS), in participants with mCSPC…